S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$108.41
+0.67 (+0.62 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$108.07
Now: $108.41
$109.21
50-Day Range
$102.30
MA: $107.32
$112.62
52-Week Range
$62.55
Now: $108.41
$113.41
Volume4.68 million shs
Average Volume7.57 million shs
Market Capitalization$191.44 billion
P/E Ratio22.92
Dividend Yield4.83%
Beta0.84
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AbbVie logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900
Employees47,000
Year Founded2013

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.13 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Outstanding Shares1,765,882,000
Market Cap$191.44 billion
Next Earnings Date5/7/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.81 out of 5 stars

Medical Sector

4th out of 1,966 stocks

Pharmaceutical Preparations Industry

2nd out of 772 stocks

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
$108.41
+0.67 (+0.62 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie
or view top-rated stocks.

What stocks does MarketBeat like better than AbbVie?

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AbbVie wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its earnings results on Tuesday, February, 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.85 by $0.07. The company earned $13.86 billion during the quarter, compared to analyst estimates of $13.70 billion. AbbVie had a trailing twelve-month return on equity of 439.24% and a net margin of 18.16%. AbbVie's revenue for the quarter was up 59.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.21 earnings per share.
View AbbVie's earnings history
.

How has AbbVie's stock been impacted by COVID-19?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABBV stock has increased by 27.8% and is now trading at $108.41.
View which stocks have been most impacted by COVID-19
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 18th. Investors of record on Thursday, April 15th will be given a dividend of $1.30 per share on Friday, May 14th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 4.80%. The ex-dividend date is Wednesday, April 14th.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.20 per share and currently has a dividend yield of 4.83%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 58.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.73% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY21 earnings guidance on Wednesday, February, 3rd. The company provided earnings per share guidance of $12.32-12.52 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.19.

What price target have analysts set for ABBV?

18 equities research analysts have issued 12-month price targets for AbbVie's shares. Their forecasts range from $95.00 to $140.00. On average, they expect AbbVie's stock price to reach $115.50 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for AbbVie
or view top-rated stocks among Wall Street analysts.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 67, Pay $7.11M)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 55, Pay $3.98M)
  • Mr. Robert A. Michael, Exec. VP & CFO (Age 51, Pay $2.76M)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 58, Pay $4.3M)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 58, Pay $4.08M)
  • Dr. Azita Saleki-Gerhardt, Exec. VP of Operations (Age 58)
  • Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Shea, VP of Investor Relations
  • Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 55)
  • Mr. Scott C. Brun M.D., VP of Scientific Affairs & Head of AbbVie Ventures

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.05%), Price T Rowe Associates Inc. MD (1.84%), FMR LLC (1.65%), Northern Trust Corp (1.35%), Bank of New York Mellon Corp (1.18%) and Janus Henderson Group PLC (1.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, American International Group Inc., Davidson Kempner Capital Management LP, AJO LP, FMR LLC, FIL Ltd, and PGGM Investments. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
or view top insider-selling stocks.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, Morgan Stanley, BlackRock Inc., UBS Asset Management Americas Inc., Principal Financial Group Inc., Janus Henderson Group PLC, Mackenzie Financial Corp, and Amundi Pioneer Asset Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $108.41.

How much money does AbbVie make?

AbbVie has a market capitalization of $191.44 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 47,000 workers across the globe.

When was AbbVie founded?

AbbVie was founded in 2013.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

Where are AbbVie's headquarters?

AbbVie is headquartered at 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.